Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
42.33
+0.29 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
June 30, 2023
From
Genentech
Via
Business Wire
Monkeypox Vaccine: Blue Water Biotech Touts Encouraging Preclinical Data From Monkeypox Vaccine Candidate
June 28, 2023
Blue Water Biotech Inc (NASDAQ: BWV) has released preliminary preclinical data that supports the potential use of its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform for the...
Via
Benzinga
Agilent Technologies Stock: Ready to Rise off the Floor
June 21, 2023
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.
Via
MarketBeat
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
June 16, 2023
The FDA approved Roche Holding AG's (OTC: RHHBY) Columvi (glofitamab-gxbm) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL)...
Via
Benzinga
Stock Analysis: Roche Holding AG
May 16, 2023
Roche is a Swiss biopharmaceutical and diagnostic company.
Via
Talk Markets
FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 15, 2023
From
Genentech
Via
Business Wire
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
June 14, 2023
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and
Via
Benzinga
New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
June 09, 2023
Roche Group Holdings AG's (OTC: RHHBY) data from the global phase 3 COMMODORE 1 and 2 studies e
Via
Benzinga
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 09, 2023
From
Genentech
Via
Business Wire
Why Shares of Zentalis Pharmaceuticals Dropped This Week
June 02, 2023
A rash of insider selling meant the stock gave back some of its gains from last week.
Via
The Motley Fool
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
May 26, 2023
Roche tested its treatment in patients with liver cancer and found "meaningful" results.
Via
Investor's Business Daily
Why Shares of Rain Oncology Are Plummeting Today
May 22, 2023
The company released disappointing top-line results for its lead oncology therapy.
Via
The Motley Fool
Apple Thwarts $2B In Fraud Transactions, UBS Takes $17B Hit From 'Hasty Credit Suisse Takeover,' Verizon Streamlines Unlimited Data Plans: Today's Top Stories
May 17, 2023
Benzinga
Via
Benzinga
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
May 17, 2023
Roche Holdings AG's (OTC: RHHBY) Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS)
Via
Benzinga
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
May 17, 2023
From
Genentech
Via
Business Wire
3 Stocks That Are Reshaping the Future
May 16, 2023
As the population ages and AI develops, these three companies stand out among stocks reshaping the future.
Via
InvestorPlace
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
May 16, 2023
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
Via
MarketBeat
Exposures
Product Safety
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
May 13, 2023
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr....
Via
Talk Markets
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
May 09, 2023
From
Genentech
Via
Business Wire
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
May 05, 2023
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.
Via
MarketBeat
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials
May 04, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176.
Via
Benzinga
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish
April 28, 2023
Tempest Therapeutics Inc (NASDAQ: TPST) announced
Via
Benzinga
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost?
April 27, 2023
The company reported lighter-than-expected declines due to Keytruda and Gardasil.
Via
Investor's Business Daily
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline
April 26, 2023
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)
Via
Benzinga
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls
April 26, 2023
Both GSK and Roche experienced declining Covid-related sales in the first quarter.
Via
Investor's Business Daily
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial
April 26, 2023
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at...
Via
Benzinga
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
April 25, 2023
From
Genentech
Via
Business Wire
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
All three companies have therapies with strong sales potential.
Via
The Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
April 25, 2023
The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.
Via
Benzinga
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
April 24, 2023
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.